Clinical trials: Bladder Cancers
Non Muscle Invasive Bladder Cancer
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have…
- Trial name
- CORE-001 (NCT04387461)
- Testing
- CG0070, Pembrolizumab Injection, n-dodecyl-B-D-maltoside
- Where
- 19 sites in United States, South Korea
- Volunteers
- 35 people
- Sponsor
- CG Oncology, Inc.
Bladder Cancer
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer
This is a single-arm study investigating the safety, feasibility and diagnostic performance of AI-assisted Uro-Cam catheter assessment that will be performed at the Prince of Wales Hospital.
- Trial name
- NCT07095751
- Testing
- AI Uro-Cam
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Bladder Cancer
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Background: Many cancers produce two particular proteins. The immune system can target these to attack the cancer. The PANVAC vaccine puts genes for these proteins inside a virus vaccine so the body sees the proteins as foreign…
- Trial name
- NCT02015104
- Testing
- BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Patient Satisfaction, Bladder Cancer
Ileal Conduit Versus Cutaneous Ureterostomy After Radical Cystectomy
Bladder cancer is the most common malignancy of the urinary tract and accounts for about 3.2% of all cancer worldwide where it remains the seventh most commonly diagnosed malignancy in the male population.
- Trial name
- NCT04610385
- Testing
- radical cystectomy with urinary diversion
- Volunteers
- 40 people
- Sponsor
- Assiut University
Urothelial Bladder Cancer
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
This is a Phase 2 clinical intervention trial to assess efficacy of induction EVP to spare the bladder in stage T2-4aN0-1 urothelial bladder cancer (UBC), using a response-adapted approach
- Trial name
- FIDELIO (NCT07663747)
- Testing
- Enfortumab Vedotin, Pembrolizumab, Radiation
- Where
- 3 sites in Netherlands
- Volunteers
- 56 people
- Sponsor
- The Netherlands Cancer Institute
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
This phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer.
- Conditions
- High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT05843448
- Testing
- PD-L1/IDO Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Locally Advanced or Metastatic Urothelial Carcinoma
Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma
Phase II, multicenter, non-randomized, single-arm, open-label trial of atezolizumab in combination of split-doses of gemcitabine plus cisplatin in patients with locally advanced or metastatic urothelial carcinoma.
- Trial name
- AUREA (NCT04602078)
- Testing
- Atezolizumab 1200 mg/m2, Gemcitabine 1000 mg/m2, Cisplatin 70 mg/m2
- Where
- 12 sites in Spain
- Volunteers
- 82 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
The goal of this clinical trial is to learn if gemcitabine/cisplatin plus cemiplimab with or without fianlimab works to treat bladder cancer in adults.
- Trial name
- NeoSTOP-IT (NCT06571708)
- Testing
- Gemcitabine, Cisplatin, Cemiplimab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Columbia University
Bladder Cancer Requiring Cystectomy, Ureteral Stents
STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy
Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or…
- Trial name
- NCT07655284
- Testing
- ureteral stents, no ureteral stent
- Where
- 2 sites in United States, Brazil
- Sponsor
- Brigham and Women's Hospital
Bladder Cancer
Compare the Quality of Life Between Patients With Conduit Diversions or Orthotopic Neobladders
The aim of this study is to compare the health-related quality of life (HRQoL) between patients underwent conduit diversion and orthotopic neobladder after radical cystectomy.
- Trial name
- NCT02174185
- Testing
- validated health-related quality of life questionnaires
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huazhong University of Science and Technology
Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
This is a prospective, multicenter, randomized controlled superiority study designed to evaluate whether the addition of pelvic lymph node dissection improves bladder-intact event-free survival in patients with cT2-3N0M0 bladder…
- Conditions
- Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
- Trial name
- NCT07756008
- Testing
- Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Tianjin Medical University Second Hospital
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin…
- Conditions
- Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
- Trial name
- NCT02844816
- Testing
- Atezolizumab
- Where
- 272 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- National Cancer Institute (NCI)
Non-Muscle Invasive Bladder Cancer
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.
- Trial name
- BicaBCa (NCT05327647)
- Testing
- Bicalutamide, Control Arm
- Where
- 7 sites in Canada
- Volunteers
- 160 people
- Sponsor
- CHU de Quebec-Universite Laval
Suspicion of Bladder Cancer, NMIBC Surveillance
Bladder EpiCheck Product Development Study
This is a prospective, observational study to support the development of the Bladder EpiCheck kit by collecting urine samples from subjects suspected to have a bladder tumor or under NMIBC surveillance.
- Trial name
- NCT07514143
- Testing
- Bladder EpiCheck
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Nucleix Ltd.
Bladder Cancer
Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)
Randomized clinical trial aiming to assess Holmium Laser En Bloc Resection Of Bladder Tumor (HoLERBT) in comparison with Conventional Transurethral Resection Of Bladder Tumors (cTURBT) in tumor histopathological staging quality…
- Trial name
- HoLERBT (NCT02555163)
- Testing
- HoLERBT, cTURBT
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Mansoura University
Bladder Cancer
Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer
Open label, randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer.
- Trial name
- BCG+MM (NCT02948543)
- Testing
- Bacillus of Calmette-Guerin (BCG), Mitomycin (MM)
- Where
- 17 sites in Australia, United Kingdom
- Volunteers
- 501 people
- Sponsor
- University of Sydney
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
A single-arm, prospective, exploratory clinical trial to explore the pathological complete response (pCR) rate of immune checkpoint inhibitors combined with antibody conjugate drugs as the perioperative treatment of…
- Trial name
- NCT06341400
- Testing
- DisitamabVedotinForIicction Toripalimab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Zhujiang Hospital
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Bladder Cancer
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00014287
- Testing
- gemcitabine hydrochloride
- Sponsor
- University of Pittsburgh
Cervical Cancer, Radical Hysterectomy
Removal of Urinary Catheter After Radical Surgery
Currently, the treatment of cervical cancer in early stages is performed with a radical surgery called Radical Hysterectomy with Pelvic Lymphadenectomy.
- Conditions
- Cervical Cancer, Radical Hysterectomy, Bladder Dysfunction
- Trial name
- NCT03570593
- Testing
- REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY
- Volunteers
- 95 people
- Sponsor
- Barretos Cancer Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.